EDUCATION:
09/1992 - 08/1996 - B.S., Anhui Agriculture University, Hefei, China
09/1996 - 08/1999 - M.S., Anhui AgricultureUniversity, Hefei, China
09/1999 - 01/2003 - Ph.D., Zhejiang University, Hangzhou, China
POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS:
02/2003 - 11/2004 - Postdoctoral Fellow, Bioinformatics and Statistical Genetics, Osteoporosis Research Center, Creighton University, Omaha, NE
12/2004 - 07/2007–Research Fellow, Bioinformatics and Cancer Genetics, Dept of Surgery and Siteman Cancer Center, Washington University, St Louis, MO
08/2007 - 7/2008 – Senior Scientist, Bioinformatics and Cancer Genetics, Dept of Surgery and Siteman Cancer Center, Washington University, St Louis, MO
FACULTY APPOINTMENTS:
08/2008 - 08/2010 -Research Assistant Professor, Department of Surgery, Washington University, St Louis, MO
09/2010–08/2014 - Assistant Professor, Department of Physiology &Cancer Center, The Medical College of Wisconsin, Milwaukee, WI
09/2014 –current - Professor, Institute of Translational Medicine and Women’s hospital, Zhejiang University, Hangzhou, Zhejiang, China
AWARDS AND HONORS:
09/1999 - Excellent Student Award, Zhejiang University, China.
PROFESSIONAL SOCIETIES:
Member, American Society of Human Genetics
Member, American Society of Cancer Research
Reviewer: Bioinformatics
Reviewer: Genetica
Reviewer: PLoS One
Reviewer:Osteoporosis International
Reviewer: Molecular Carcinogenesis
Reviewer: Physiology Genomics
Reviewer: Journal of Thoracic Oncology
Reviewer: Briefs of Bioinformatics
RESEARCH GRANTS/AWARDS/CONTRACTS/PROJECTS:
Ongoing Research Support
National Natural Science Foundation of China 1/1/2018 – 12/30/2021
Genome-wide discovery of circRNAs as prognostic biomarkers in early ovarian cancer
This proposal will identify a powerful circRNA-based expression signature that can accurately predict overall survival and recurrence of patients with ovarian cancer.
Role: PI
Direct cost: ￥550,000
National Natural Science Foundation of China 1/1/2015 – 12/30/2018
CREBBP mutations, a novel prognosis biomarker for ovarian cancer relapse and personalized medicine
This proposal will uncover novel roles for CBP in ovarian cancer development and potential combination therapy strategy for ovarian carcinoma with aberrant CBP.
Role: PI
Direct cost: ￥720,000
Completed:
National Natural Science Foundation of China 1/1/2015 – 12/30/2017
The Analyzing Method and Tool of Identifying Driver Genes and Pathways in Cancer Genome Sequencing
This proposal will develop and improve DrGaP by two important extensions: 1) functional consequence of different non-silent mutations and 2) tumor mutation heterogeneity.
Role: PI
Direct cost: ￥250,000
National Lung Cancer Partnership- FP00004228 (Lu) 1/1/2013 – 12/30/2014
The molecular mechanisms of Dock9 underlying lung carcinogenesis
This proposal will determine the molecular mechanisms by which Dock9 confers susceptibility to lung cancer.
Role: PI
Direct cost: $100,000
1R01CA129533-01A1(You) 7/17/08-3/31/11
NCI
Molecular Characterization of Stage I Lung Cancer
This study is to validate the 64-gene signature using custom-designed RNA array and tissue microarray in 300 stage I NSCLC cases from the Cancer and Leukemia Group B (CALGB) lung cancer study 140202.
Role: Co-Investigator.
HHSN-261200433008C (N01-CN43308) (You, Lu) 12/01/08-9/31/10
NCI (Preclinical Efficacy & Intermediate Biomarker Assays)
The Use of Microarrays in Examining Gene Expression Changes Induced by a Variety of Agents in Both Normal Tissues and Cancers This proposal applies micrroarrays to study chemoprevention efficiency of multiple agents, including RXR agonists, Phase I/II inducers, naproxen, NO-naproxen, NO releasing agent, sulindac, sulindacsulfone and NO-sulindacis in several rodent cancer models.
Role: co-PI.
WHRP Grant –FP00003759 (Lu) 7/1/2012 – 6/30/2013
CREBBP mutations predict relapse of ovarian carcinoma
This proposal will test if mutations in CREBBP impair acetylation activity and subsequently lead to poor prognosis in patients with HGS-OvCa.
Role: PI
Direct cost: $50,000
Research Affairs Committee- FP00004478 (Lu) 1/1/2013 – 12/30/2013
The role of hypoxia-induced microRNAs in lung tumor metastasis
This project will characterize the molecular mechanisms by which hypoxia-induced aberrant expression of microRNAs and their regulatory networks determine the aggressiveness and metastatic potential of cancer cells.
Role: PI
Direct cost: $25,000
AHW- FP00001703 (Lu) 11/1/2010 – 8/31/2014
Advancing a Healthier Wisconsin
AHW Chemoprevention Program Recruitment_Lu
The proposed Cancer Chemoprevention Program is one of the key research programs of the Medical College of Wisconsin Cancer Center. The goals of research in the Program are to develop candidate chemopreventive agents in preclinical studies with known mechanisms of action, and to evaluate the efficacy of these agents for cancer prevention in high-risk human populations.
Role: PI
Direct cost: $603,896
TEACHING ACTIVITIES:
Teaching Assistant, Graduate Course “Genetic Data Analysis”, February-May 2002, Zhejiang University, Hangzhou, China.
Teaching Assistant,Undergraduate Course “Genetics and Plant Breeding”, September -December 1998, Anhui Agricultural University, Hefei, China.
